C
Christine Baudelet
Researcher at Bristol-Myers Squibb
Publications - 24
Citations - 9781
Christine Baudelet is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 16, co-authored 24 publications receiving 7789 citations.
Papers
More filters
Journal ArticleDOI
A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).
David R. Spigel,Karen L. Reckamp,Naiyer A. Rizvi,Elena Poddubskaya,Howard Jack West,Wilfried Eberhardt,Paul Baas,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Rudy Aren,Leora Horn,Luis Paz-Ares,Christine Baudelet,Brian Lestini,Julie R. Brahmer +19 more
TL;DR: Results are reported of a randomized, open-label, global trial of platinum-based doublet chemotherapy in patients with advanced SQ NSCLC who fail platinum-Based Doublet chemotherapy (PT-DC).
Journal ArticleDOI
ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,N. Fujimoto,Solange Peters,Anne Tsao,Aaron S. Mansfield,Sanjay Popat,T. Jahan,S.J. Antonia,Youssef Oulkhouir,Y. Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Christine Baudelet,Gérard Zalcman +19 more
Journal ArticleDOI
A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder
Rif S. El-Mallakh,Ronald N. Marcus,Christine Baudelet,Robert D. McQuade,William H. Carson,Randall Owen +5 more
TL;DR: Aripiprazole monotherapy appears to be equivalently useful to lithium for the extended treatment of mixed or manic bipolar disorder patients and long-term completion rates were low in both groups.
Journal ArticleDOI
A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
Athanassios Argiris,Maura L. Gillison,Robert L. Ferris,K.J. Harrington,T.K. Sanchez,Christine Baudelet,William J. Geese,James W. Shaw,Robert I. Haddad +8 more
Journal ArticleDOI
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
Jean-Luc Raoul,Joong-Won Park,Yoon-Koo Kang,Richard S. Finn,Jun Suk Kim,Winnie Yeo,Blase N. Polite,Yee Chao,Ian Walters,Christine Baudelet,Riccardo Lencioni +10 more
TL;DR: Tumor response as assessed by m RECIST differed from that by WHO criteria, with mRECIST possibly identifying true nonresponders with a poor prognosis.